CAS: 91188-13-5; Tert-Butyl Azetidin-3-Ylcarbamate

该化合物是一种化学化合物,其特点是其芳香环结构,即四人组成的饱和异环化合物,内含一个氮原子."N-Boc"的称谓表明,氨基化合物组受一个三丁基碳氢化合物(Boc)组的保护,该组是有机合成中的一个共同保护群体,可增强稳定性和溶性.该化合物一般用于合成药物和生物活性分子的合成,因为它有能力作为浸泡合成和其他有机反应的构件.它一般是白色至白色的固体,其特性包括有机溶剂中的中度.由于存在该组,可以在温酸条件下有选择地进行保护,从而便利了亚丁基锡环的进一步功能化.与许多含氮的乙型循环一样,它可能展示有趣的生物活动,使其成为医药化学的一个主题.在处理和储存时,应参考安全数据,因为与所有化学物质一样.

结构式图片

相似化合物

217806-26-3 218430-15-0 1521828-13-6

欧盟法规

C&L通报

合成工艺路线路线简述

  • 合成目标产物 3-N-Boc-Amino-Azetidine 主要起始原料 Tert-Butyl 1-Benzhydryl-3-Azetidinylcarbamate
  • 91189-18-3 = 91188-13-5
    反应条件:1.1 Reagents: Hydrochloric Acid,Ammonia Catalysts: Palladium Solvents: Ethanol,Water
    标题:Semisynthetic β-Lactam Antibiotics. Iii. Synthesis And Antibacterial Activity Of 7β-[2-(2-Aminothiazol-4-Yl)-2-(Substituted Carbamoylmethoxyimino)Acetamido]Cephalosporins
    作者:Arimoto,Masahiro; Et Al
    参考文献:Journal Of Antibiotics 日期:1986 卷标:39(9) 页码:1243-56]

    40432-52-8 + 58632-95-4 = 91188-13-5
    反应条件:1.1 Reagents: Triethylamine Solvents: 1,4-Dioxane,Water2.1 Reagents: Hydrochloric Acid,Ammonia Catalysts: Palladium Solvents: Ethanol,Water
    标题:Semisynthetic β-Lactam Antibiotics. Iii. Synthesis And Antibacterial Activity Of 7β-[2-(2-Aminothiazol-4-Yl)-2-(Substituted Carbamoylmethoxyimino)Acetamido]Cephalosporins
    作者:Arimoto,Masahiro; Et Al
    参考文献:Journal Of Antibiotics 日期:1986 卷标:39(9) 页码:1243-56]

    33301-41-6 = 91188-13-5
    反应条件:1.1 Reagents: Ammonia Solvents: Methanol2.1 Reagents: Triethylamine Solvents: 1,4-Dioxane,Water3.1 Reagents: Hydrochloric Acid,Ammonia Catalysts: Palladium Solvents: Ethanol,Water
    标题:Semisynthetic β-Lactam Antibiotics. Iii. Synthesis And Antibacterial Activity Of 7β-[2-(2-Aminothiazol-4-Yl)-2-(Substituted Carbamoylmethoxyimino)Acetamido]Cephalosporins
    作者:Arimoto,Masahiro; Et Al
    参考文献:Journal Of Antibiotics 日期:1986 卷标:39(9) 页码:1243-56
📜1-二苯甲基氮杂环丁烷-3-氨基甲酸叔丁酯置于palladium Dihydroxide 盐酸,氢气体系中,用 1,4-二氧六环,甲醇 作为反应溶剂,化学反应生成 3-N-叔丁氧羰基胺基环丁胺
参考文献: Guanidino-Substituted Quinazolinone Compounds As Mc4-R Agonists[fr] Composes De Quinazoline Substitues Par Guanidino Constituant Des Agonistes De Mc4-R
标题: Guanidino-Substituted Quinazolinone Compounds As Mc4-R Agonists[fr] Composes De Quinazoline Substitues Par Guanidino Constituant Des Agonistes De Mc4-R
摘要:提供了一系列含有胍基的小分子化合物,能够作为mc4-R激动剂.当这些化合物被给予受试者时,它们对治疗mc4-R介导的疾病是有用的.这些化合物具有结构ia,Ib和ic,其中变量的值在此定义.

海关参考信息

专利信息


专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人:GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:US-9868746-B2
优先权日:2012-02-23
标题:Substituted 5-aminothieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
发明人:LINDSLEY CRAIG W; CONN P JEFFREY; WOOD MICHAEL R; MELANCON BRUCE J; TARR JAMES C; SALOVICH JAMES M; POSLUSNEY MICHAEL S
权利人:UNIV VANDERBILT
摘要:In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M 4 (mAChR M 4 ); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

专利号:US-4870169-A
优先权日:1985-07-17
标 题:Intermediates for beta-lactam antibiotics
发明人:EVANS DAVID A; SJOGREN ERIC B
权利人:HARVARD COLLEGE
摘要:1-Benzyl(or substituted benzyl)-3β-[4(S)-aryloxazolidin-2-one-3-yl]-4β-(2-arylvinyl)azetidin-2-ones are provided via cycloaddition of a 4(S)-aryloxazolidin-2-one-3-ylacetyl halide and an imine formed with a benzylamine and a 3-arylacrolein, e.g. cinnamaldehyde. The azetidinones are useful chiral intermediates in an asymmetric synthesis of 1-carba(1-dethia)-3-hydroxy-3-cephem-4-carboxylic acids and esters and to monocyclic β-lactam antibiotics.

专利号:US-2013060019-A1
优先权日:2011-09-07
标 题 :Compounds for Use in Treating Neurodegenerative Disorders, Synthesis Thereof, and Intermediates Thereto
发明人:BRONK BRIAN SCOTT; AUSTIN WESLEY FRANCIS; CREASER STEFFEN PHILLIP; FULLER NATHAN OLIVER; HUBBS JED LEE; SHEN RUICHAO
权利人:BRONK BRIAN SCOTT; AUSTIN WESLEY FRANCIS; CREASER STEFFEN PHILLIP; FULLER NATHAN OLIVER; HUBBS JED LEE; SHEN RUICHAO; SATORI PHARMACEUTICALS INC
摘要:The present invention provides methods of making a compound of formula II: n n n n n n n n n n or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , and L are as defined and described herein.

专利号:US-4665171-A
优先权日:1985-07-17
标 题:Process and intermediates for β-lactam antibiotics
发明人:EVANS DAVID A; SJOGREN ERIC B
权利人:UNIV HARVARD
摘要:1-Benzyl (or substituted benzyl)-3β-[4(S)-aryloxazolidin-2-one-3-yl]-4β-(2-arylvinyl)azetidin-2-ones are provided via cycloaddition of a 4(S)-aryloxazolidin-2-one-3-ylacetyl halide and an imine formed with a benzylamine and a 3-arylacrolein, e.g. cinnamaldehyde. The azetidinones are useful chiral intermediates in an asymmetric synthesis of 1-carba(1-dethia)-3-hydroxy-3-cephem-4-carboxylic acids and esters and to monocyclic β-lactam antibiotics.

专利号:US-2023090060-A1
优先权日:2020-01-22
标题:Synthesis and application of class of respiratory syncytial virus inhibitors

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.1126/science.abo7201
摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知